In a nutshell This study compared the safety and effectiveness of pyrotinib (SHR-1258) plus capecitabine (Xeloda) versus lapatinib (Tyverb) plus capecitabine in patients with metastatic human epidermal growth factor (HER2)-positive breast cancer (BC) after previous treatment with trastuzumab (Herceptin) and chemotherapy. The data...
Read More
In a nutshell The authors assessed the safety and effectiveness of umbralisib (Ukoniq) in patients with relapsed or refractory (r/r) indolent (low-grade) non-Hodgkin lymphoma (iNHL). The study concluded that umbralisib was well tolerated and effective for patients with r/r iNHL. Some background iNHL is a slow-growing cancer of...
Read More
In a nutshell This study aimed to investigate the effectiveness of DPd (daratumumab, pomalidomide, and dexamethasone) as salvage therapy followed by high dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) for relapsed/refractory (RR) multiple myeloma (MM). The study concluded that this therapy is effective and well tolerated...
Read More
In a nutshell The authors assessed the safety and efficacy of involved-field radiotherapy (IFRT) after autologous hematopoietic stem-cell transplantation (ASCT) in patients with high-risk relapsed/refractory (r/r) lymphoma. The study found that IFRT given soon after ASCT provided durable responses and was well tolerated in these patients. Some...
Read More
In a nutshell The authors assessed the safety and efficacy of involved-field radiotherapy (IFRT) after autologous hematopoietic stem-cell transplantation (ASCT) in patients with high-risk relapsed/refractory (r/r) lymphoma. The study found that IFRT given soon after ASCT provided durable responses and was well tolerated in these patients. Some...
Read More
In a nutshell This study looked at 5-year outcomes of patients with previously treated advanced non-small-cell lung cancer (NSCLC) taking nivolumab (Opdivo) compared to docetaxel (Taxotere). The authors found that nivolumab continued to improve the outcomes of these patients after 5 years. Some background NSCLC is the most common...
Read More
In a nutshell This study investigated the effectiveness and safety of combination regimens of brentuximab vedotin (BV; Adcetris), ipilimumab (Yervoy), and nivolumab (Opdivo) in patients with relapsed/refractory Hodgkin lymphoma (HL). The data showed that the treatment combinations had promising effectiveness and manageable side effects. Some background...
Read More
In a nutshell This study reported the long-term effectiveness and safety outcomes of treatment with idelalisib (Zydelig) after a longer follow-up of patients with indolent (painless) non-Hodgkin lymphoma. The data showed that idelalisib treatment improved the overall survival of these patients in the long-term. Some background Non-Hodgkin...
Read More
In a nutshell This study aimed to evaluate the safety and effectiveness of loncastuximab tesirine (LoT; Lonca) for the treatment of patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). The study found that LoT was safe and had promising activity in these patients. Some background B-NHL is a type of...
Read More
In a nutshell This phase 2 clinical trial is evaluating the safety and effectiveness of targeted therapy TAS-120 (futibatinib) alone or in combination with fulvestrant (Faslodex) in patients with metastatic breast cancer (mBC). The main outcomes to be evaluated will be the response rate and survival without cancer worsening. The details Breast...
Read More
In a nutshell This study aimed to investigate the outcomes for patients with multiple myeloma (MM) who were treated with pomalidomide (Pomalyst), bortezomib (Velcade), and dexamethasone (Decadron) after relapsing following lenalidomide (Revlimid) treatment. This study concluded that this treatment combination was effective in...
Read More
In a nutshell This trial is being carried out to assess the safety and effectiveness of an experimental drug called BCA101 alone and in combination with pembrolizumab (Keytruda) in advanced solid tumors that are EGFR-positive. The main outcomes to be measured are the occurrence of side effects and response to treatment. The details Advanced solid...
Read More
